Category Archives: AZBio News

We Asked. You Answered. Here’s your 2013 AZBio Viewpoint Results

Posted on by

Beginning in fourth quarter of 2012, AZBio put out the call across Arizona’s bioscience community and asked….”What’ your viewpoint?”

Members of Arizona’s bioscience community from across the state answered via a short survey focused on both policy and action priorities.

Respondents ranked priorities on a scale from 5 to 1 with a 5 being “Most Important”  and a 1 being “Least Important”.

Topping the list for policy priorites is the capital we need to grow, followed closely by policies that attract and grow companies within our industry.

5 Highest Priorities for Public Policy:

  1. Access to growth capital  (79% of respondents rating with a 4 or 5 – Average Score 4.1)
  2. State and local policies that promote the attraction and growth of companies in the Arizona Bioscience Industry  (75% of respondents rating with a 4 or 5 – Average Score 4.0)
  3. Access to a qualified bioscience talent pool (71 % of respondents rating with a 4 or 5- Average Score 3.4)
  4. State financial support for the continued growth of Arizona’s research universities  ( 70% of respondents rating with a 4 or 5 – Average Score 3.9)
  5. State and local financial support for the continued growth of Arizona’s Medical Schools  (64 % of respondents rating with a 4 or 5- Average Score 3.7)

 Top 5 Priorities for AZBio Actions and Activities

  1. Working with Angels, Venture Capital, and Financial Institutions to expand opportunities for Arizona Bioscience Companies to access growth capital.  (80 % of respondents rating with a 4 or 5- Average Score 4.2)
  2. Working with educators to promote interest in bioscience education and for their students, interest and preparation for bioscience careers  (74 % of respondents rating with a 4 or 5- Average Score 3.9)
  3. Spreading the word about the the value created by Arizona’s Bioscience Industry (72 % of respondents rating with a 4 or 5- Average Score 3.9)
  4. Advocating for our industry at the state and local level (71 % of respondents rating with a 4 or 5- Average Score 4.0)
  5. Regional Educational Events: Bioscience and Business Speakers  (68 % of respondents rating with a 4 or 5- Average Score 3.7)

 

To view the AZBio Viewpoint results in 2012, click here.

Survey note:  The AZBio Viewpoint Survey was open to all members of the Arizona bioscience community from November, 2012 until January 2013 and responses were receved from across the state of Arizona.

  • 62% of responses were received from Arizona Bioscience Companies and Research Insitutions.
  • 80% of responses were received from Arizona Bioindustry Association Member Organizations
  • Respondents self represented their company size as follows:
    • 1-10 employees – 48%
    • 11-100 employees – 20%
    • 100+ – 22%

Did you miss participating in the survey?  Additional views are welcome.  To share yours, complete the Viewpoint Survey here .

PhRMA Report: “Innovation in the Biopharmaceutical Pipeline: A Multi-Dimensional View”.

Posted on by

This morning PhRMA released a report, “Innovation in the Biopharmaceutical Pipeline: A Multi-Dimensional View”. The paper, by researchers at Analysis Group, examines the pipeline from several angles and helps to show the range of innovative research our companies are doing.

 

The reports find:

  • More than 5,000 medicines are in development globally
  • 70% of medicines in development are potentially first-in-class
  • Personalized medicines and drugs for rare diseases are rapidly growing parts of the drug development pipeline
  • Researchers are pursuing many new scientific approaches such as conjugated monoclonal antibodies and therapeutic cancer vaccines

Video streaming by Ustream
PhRMA’s  reports are part of their ongoing efforts to communicate the important contributions PhRMA companies are making to save and improve lives.

Resources

Report: Analysis Group Report

Report: Accompanying PhRMA Report

Release: Robust Biopharmaceutical Pipeline Offers New Hope for Patients

Related Press Coverage USA Today AP News

Related Blog Posts

Examining the Biopharmaceutical Pipeline – Webinar Jan 14, 2013

PhRMA Hosting Webinar Highlighting New Exciting Medicines in the Biopharmaceutical Pipeline January 11, 2013

 

Biocentury This Week: Computing for Cures

Posted on by

From Cold War computing on the West Coast to genome sequencing in Manhattan and FDA data mining in Washington, how advances in computer hardware and software promise to transform how drugs are discovered and developed.

The newest edition of BioCentury This Week television is joined by:

•

Dr.   Fred Streitz,   Director of the Institute for Scientific Computing Research at Lawrence   Livermore National Laboratory, who explains how high-performance computing is   being used to precisely simulate 370 million cells in the human heart.
•

Dr.   Eric Perakslis,   Chief Information Officer at FDA, on the agency’s progress in harnessing   mountains of clinical trial data.
•

Nancy   Kelley,   Executive Director and COO of the New York Genome Center, who describes the Big Apple’s ambitious efforts to merge medicine and information technology.

BioCentury 01.13.13 - [1] Extreme Levels
NOTICE:     BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content  on “BioCentury This Week,” and except for limited use of these links to the  BioCenturytv.com website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury  This Week content to any unauthorized third party websites such as YouTube. Other  BioCenturytv.com content and all trademarks   are the property of BioCentury or WUSA-TV or other third parties.